Dr. Zou assists clients in
matters involving all types of intellectual property: patents, trade secrets,
and unfair competition. He focuses mainly on intellectual property strategic
consulting, patent portfolio management, patent infringement, validity, and
freedom-to-operate opinions, due diligence, and dispute resolution;
representing many multinational pharmaceutical companies, small and
medium-sized innovative companies in handling intellectual property, drug
regulatory matters and market admission related legal affairs.
The wide variety of
technical areas in which Dr. Zou has obtained and enforced patent protection
for clients include pharmacy, chemistry, and biotechnologies, as well as
mechanical systems and medical devices.
Dr. Zou started his IP career
with Liu Shen in 2003. Prior to his legal profession, Dr. Zou was engaged in
research and development in pharmaceutical research and diagnostic method
development, he is very familiar with the technical areas of pharmaceuticals,
nucleic acid, pesticide, macromolecule modification, and molecular diagnostics.
EDUCATION &TRAINING
Dr. Zou obtained his Ph.D.
in pharmaceutical chemistry at the Chinese Academy of Military Medical Science
(China, 2000), and his Master of Laws in Intellectual Property Law from John
Marshall Law School (the U.S., 2010).
Representative cases that Dr. Zou has led or
participated include
- Defending titropium bromide patent portfolio for
Boehringer Ingelheim (German) in the invalidation proceedings and in court
procedures (5 patents involved, 2006-2012);
- Defending Candesartan Cilexetil patent portfolio for
Takeda (Japan) in the invalidation proceedings and in court procedures ( 2
patents involved, 2007-2012);
- Representing Albis in Albis (Germany) vs. FTP China,
invalidation & infringement cases (settled, 2012-2014);
- Representing Grundfos in Grundfos (Denmark) vs.
Zhejiang Qianyuan (China), infringement case, the Beijing High Court
(infringement found and damage awarded, 2013-2014);
- Representing Shanghai Cathay Biotech in Shanghai
Cathay Biotech vs. Hilead Biotech (2013-2014) and won three administrative
cases;
- Representing Xiamen Hongfa in Xiamen Hongfa (China)
vs. Dou Xiuzhi (2013-2014) and winning two invalidation cases;
- Representing SEB in SEB (France) vs. Wenzhou Household
electrical (2013-2014) and winning the invalidation case;
- Representing Shenzhen MINDRAY in Shenzhen MINDRAY
vs. Edan (2013-2014) and winning in invalidation & administrative
litigation;
- Representing Hongkong PolyU in Hongkong PolyU vs.
Ritter machinery (2014) and winning the invalidation case;
- Representing Pfizer and successfully defending a
polymorph case (2019).
Publications include
- Claim
definitions Undergoing Change, China IP Focus 2014, Managing Intellectual
Property, 2014 [Co-authored]
- How to
determine novelty-conferring features for a medical use claim, China IP Focus
2015, Managing Intellectual Property, 2015 [Co-authored]
- Disclosure
requirements undergoing change, IAM Life Science (2015) [Co-authored]
- How to
make sure your patent is properly supported in China, March 2016 [Co-author]
- Implications
of recent life sciences cases in China, IAM Life Science March 2017
[Co-authored]
- Overview of regulatory reform in China, IAM Life Sciences,
2018. [Co-authored]
- Patent
practice: recent developments in life sciences in China, IAM Life Sciences 2019, pp. 51-55 [Co-authored]
- Doctrine
of equivalents for life science patents in China, IAM Life Sciences 2020, pp.
53-57 [Co-authored]
Presentation that Dr. ZOU has publicly made
include
- Overview
of IP Enforcement in China, 2012 Summit on Global IP Strategy for Corporate
Counsel, New York, USA, December 2012
- Astrazeneca
case, Prometheus case and Myriad case in a Chinese patent attorney’s
perspective, MIP, London, UK, April 2013
- Chinese
Patent practice in Pharmaceutical field, MIP, Beijing, China, June 2013
- Update
on case development in life science field, IP in Asia Forum, Silicon Valley
& Seattle, USA, May 2014
- Second
medical use protection in China, the 5th China IP Symposium (Chengdu) 2015, Chengdu,
China, November 2015;
- Eligible
subject matter & Invalidation Proceedings in China, the 253rd ACS National
Meeting, San Francisco, CA, April 2017
- Must-know
Chinese Patent Practice, 2018 CABA Investment & Entrepreneurship Symposium,
Massachusetts, September 2018